Glutamic Acid

Glutamic Acid

SCHEMBL161675

N[C@@H](CCC(=O)O)C(=O)O.[SrH2]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM8 O00222 2/20 0.95
GRM6 O15303 2/20 0.95
GRM7 Q14831 2/20 0.95
GRM4 Q14833 2/20 0.95
GSR P00390 2/20 0.95
GRIN2D O15399 1/20 0.95
GRIN3B O60391 1/20 0.95
CYP1A2 P05177 1/20 0.95
GRIK1 P39086 1/20 0.95
GRM5 P41594 1/20 0.95
GRIA1 P42261 1/20 0.95
GRIA2 P42262 1/20 0.95
GRIA3 P42263 1/20 0.95
SLC1A3 P43003 1/20 0.95
SLC1A2 P43004 1/20 0.95
SLC1A1 P43005 1/20 0.95
GRIA4 P48058 1/20 0.95
GRIN1 Q05586 1/20 0.95
GRIN2A Q12879 1/20 0.95
GRIK2 Q13002 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
D-Glutamate SCHEMBL21638311 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL2586884 1.00 GRM8 (0.95) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL10427323 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL2826642 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL2828267 0.97 GRM8 (0.90) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330484 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL1330824 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
Glutamic Acid SCHEMBL1554237 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL2201 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR
D-Glutamate SCHEMBL17127348 0.97 GRM8 (1.00) GRM8GRM6GRM7GRM4GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636311-B2 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation GALLEON LABS LLC (US) 2026-05-26 US claimed
US-20250099498-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION GALLEON LABS LLC (US) 2025-03-27 US claimed
US-12121536-B2 Strontium based compositions and formulations for pain, pruritus, and inflammation GALLEON LABS LLC (US) 2024-10-22 US claimed
US-20240041919-A1 TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION GALLEON LABS LLC 2024-02-08 US claimed
US-11801261-B2 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation GALLEON LABS LLC (US) 2023-10-31 US claimed
CN-115414265-A Composition and face cream with effects of color correction, skin tendering and moisturizing and preparation method thereof 中国科学院过程工程研究所 2022-12-02 CN claimed
US-20220323485-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION PIKE, JOSEPH D. 2022-10-13 US claimed
EP-2827847-B1 TOPICALLY ADMINISTERED STRONTIUM-CONTAINING COMPLEXES FOR TREATING PAIN, PRURITIS AND INFLAMMATION GALLEON LABS LLC (US) 2022-09-14 EP claimed
EP-3284462-B1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION GALLEON LABS LLC (US) 2022-08-03 EP claimed
US-20220054535-A1 STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION STRONTIUM NEUROGENICS INC (US) 2022-02-24 US claimed
WO-2005123193-A2 TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN OSTEOLOGIX A/S (DK) 2005-12-29 WO claimed
WO-2005123130-A2 IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR OSTEOLOGIX A/S (DK) 2005-12-29 WO claimed
WO-2005123192-A2 IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS OSTEOLOGIX A/S (DK) 2005-12-29 WO claimed
WO-2005123098-A2 PREVENTING GASTROINTESTINAL SIDE-EFFECTS WITH STRONTIUM SALTS OSTEOLOGIX A/S (DK) 2005-12-29 WO claimed
WO-2005108339-A2 HIGH YIELD AND RAPID SYNTHESES METHODS FOR PRODUCING METALLO-ORGANIC SALTS OSTEOLOGIX A/S (DK) 2005-11-17 WO claimed
EP-1534305-A2 TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS Osteologix A/S (DK) 2005-06-01 EP claimed
WO-2004098619-A2 TREATING CARTILAGE / BONE CONDITIONS WITH WATER-SOLUBLE STRONTIUM SALTS OSTEOLOGIX A/S (DK) 2004-11-18 WO claimed
EP-0416321-B1 Crystalline polyolefin composition CHISSO CORP (JP) 1994-11-09 EP claimed
US-5063264-A Molding materials CHISSO CORPORATION (JP) 1991-11-05 US claimed
EP-0416321-A1 Crystalline polyolefin composition Chisso Corporation (JP) 1991-03-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636311-B2 Topically administered strontium-containing complexes for treating pain, pruritis and inflammation SUCNR1, TRPV1, TRPV2 GRM8 800/4885GRM6 418/4885GRM7 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.